Pneumococcal Vaccines Market| Coherent Market Insights

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• PNEUMOCOCCAL VACCINES MARKET ANALYSIS
• Pneumococcal Vaccines Market, by Vaccine Type
  (PCV10, PCV13, and PPSV23), by Distribution
  Channel (Hospital Pharmacies, Retail Pharmacies,
  and Online Pharmacies) - Size, Share, Outlook,
  and Opportunity Analysis, 2018 2026
• The global pneumococcal vaccines market size is
  estimated to be valued at US 7,376.6 million in
  2018, and is expected to witness a CAGR of 7.5
  over the forecast period (2018 2026).

3

• Pneumococcal vaccine is used to prevent infection
  caused by streptococcus pneumoniae bacteria.
  There are two types of pneumococcal vaccines
  pneumococcal conjugate vaccine and pneumococcal
  polysaccharide vaccine.
• The Centers for Disease Control and Prevention
  (CDC) recommends pneumococcal conjugate vaccine
  for all children younger than two years of age,
  all adults 65 years or older, and for people 2-64
  years old with certain medical conditions. The
  CDC recommends pneumococcal polysaccharide
  vaccine for all adults 65 years or older, people
  2-64 years old with certain medical conditions,
  and adults 19-64 years old who smoke cigarettes.

4

• Figure 1. Global Pneumococcal Vaccines Market
  Value (US Mn) and Absolute Opportunity
  Analysis and Forecast

5

• Increasing partnership of manufacturers with
  various governments is expected to drive growth
  of the pneumococcal vaccines market
• High mortality due to pneumonia among the global
  population is expected to increase adoption of
  pneumococcal vaccines over the forecast period.
  For instance, according to the World Health
  Organization (WHO) November 2016, pneumonia
  accounted for 16 of all deaths of children under
  5 years old in 2015, with 920,136 deaths,
  globally.
• Furthermore, increasing partnership among Global
  Alliance for Vaccines and Immunization (GAVI) and
  key vendors to deliver pneumococcal vaccines in
  emerging countries is expected to be a
  significant growth factor for the market. For
  instance, in March 2016, GSK (Glaxo Smith Kline)
  announced the introduction of pneumococcal
  vaccine at the lowest price - US 3.05 from 2017,
  a reduction of 10 from the 2016 price (US
  3.40). Such tiered pricing approach enables
  emerging economies to meet demand for vaccines
  for large proportions of the target population.
  This price is set to be available through the
  pilot Advance Market Commitment (AMC) to all GAVI
  countries. Moreover, the vaccine will be sold at
  the same price for 10 years after transition.

6
Pneumococcal Vaccines Market- Regional Analysis

• Regional segmentation of the global pneumococcal
  vaccines market by Coherent Market Insights
  comprises North America, Latin America, Europe,
  Asia Pacific, Middle East, and Africa.
• North America is expected to hold dominant
  position in the pneumococcal vaccines market.
  This is majorly due to presence of key players in
  the region, which are focused on gaining
  regulatory approvals for novel pneumococcal
  vaccines. Moreover, increasing mortality rate
  associated with pneumonia, growing awareness
  regarding pneumonia infection, and its underlying
  symptoms among the U.S. population are expected
  to contribute to significant market growth in the
  region during the forecast period. For instance,
  according to the American Lung Association 2015,
  around 56,832 deaths were registered due to
  pneumonia and influenza in 2013, which combined
  were the eighth leading cause of death in the
  U.S.
• Growing healthcare infrastructure in emerging
  economies such as India and China and increasing
  initiatives by government bodies to include
  pneumococcal vaccine in their respective
  healthcare immunization programs contribute to
  wider adoption of pneumococcal vaccines in Asia
  Pacific. For instance, in November 2016, China
  Food and Drug Administration (CFDA) approved
  Pfizer, Inc.s pneumococcal vaccine Prevenar 13,
  which is indicated to help prevent pneumococcal
  disease in infants aged between 6 weeks to 15
  months.

7
Figure 2 Global Pneumococcal Vaccines Market
Value (US Mn), By Region

8
Pneumococcal Vaccines Market- Competitive
Landscape

• Various manufacturers are focused on new projects
  that target diseases with no existing vaccine for
  various age groups. For instance, in April 2018,
  Merck, which is also known as MSD outside of the
  U.S. and Canada, started two Phase 3 studies for
  PCV-15 (V114), an investigational polyvalent
  conjugate vaccine against pneumococcal disease.
• Key players operating in the pneumococcal
  vaccines market include, Pfizer, Inc., Merck
  Co. Inc., and GlaxoSmithKline plc.
• Moreover, in 2017, the Government of India, in
  collaboration with GAVI, launched Pneumococcal
  Conjugate Vaccine (PCV) vaccines in three states
  of the country at low cost. Furthermore, under
  this partnership, 60 of all GAVI-procured
  vaccines will be manufactured in India.
• These activities coupled with increasing approval
  of vaccines are expected to support growth of
  Asia Pacific pneumococcal vaccines market over
  the forecast period.

9

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  insight/buy-now/2295

10
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

11
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

12
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/